Skip to content

Study · Animal study (in vivo) · rat · 2011

4 results

Insulin and growth hormone-releasing peptide-6 (GHRP-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (STZ)-induced diabetic rats.

Granado M, García-Cáceres C, Tuda M, Frago LM, Chowen JA, Argente J

Molecular and cellular endocrinology23 Feb 2011Cited by 10 (Europe PMC)

PMID21352888 (opens in a new tab)DOI10.1016/j.mce.2011.02.002 (opens in a new tab)PepBankPUB-21352888
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, GHRP‑6 did not decrease diabetes-induced hypothalamic cell death.

    In plain wordsIn rats with diabetes, GHRP‑6 did not reduce cell death in the hypothalamus.

    Peptide
    GHRP-6
    Outcome
    No significant changeHypothalamic cell death
    Study

    ratn: not reported in source

    streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    150 μg/kg/day · subcutaneous · 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    In the hypothalamus, neither insulin nor GHRP-6 decreased diabetes-induced cell death.
    1 context sentence
    Summary · context
    Adult male Wistar rats were made diabetic by streptozotocin injection (65 mg/kg ip) and divided into four groups from diabetes onset: those receiving a daily sc injection of saline (1 ml/kg/day), GHRP-6 (150 μg/kg/day), insulin (1-8U/day) or insulin plus GHRP-6 for 8 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, GHRP‑6 alone did not decrease cerebellar apoptosis, whereas the combined insulin regimen did.

    In plain wordsIn rats with diabetes, GHRP‑6 alone did not reduce cerebellar cell death.

    Peptide
    GHRP-6
    Outcome
    No significant changeCerebellar apoptosis
    Study

    ratn: not reported in source

    streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    150 μg/kg/day · subcutaneous · 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    In the cerebellum, although insulin treatment increased GFAP levels (P<0.01), only the combined treatment of insulin+ GHRP-6 decreased diabetes-induced apoptosis (P<0.05).
    1 context sentence
    Summary · context
    Adult male Wistar rats were made diabetic by streptozotocin injection (65 mg/kg ip) and divided into four groups from diabetes onset: those receiving a daily sc injection of saline (1 ml/kg/day), GHRP-6 (150 μg/kg/day), insulin (1-8U/day) or insulin plus GHRP-6 for 8 weeks.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In diabetic rats, insulin plus GHRP‑6 prevented the diabetes-induced decrease in hypothalamic GFAP levels.

    In plain wordsIn rats with diabetes, insulin plus GHRP‑6 prevented the decrease in hypothalamic GFAP levels.

    Peptide
    GHRP-6
    Outcome
    IncreaseHypothalamic GFAP levels
    Study

    ratn: not reported in source

    streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    However, the combined treatment of insulin+GHRP-6 prevented the diabetes induced-decrease in glial fibrillary acidic protein (GFAP) levels (P<0.05).
    1 context sentence
    Summary · context
    Adult male Wistar rats were made diabetic by streptozotocin injection (65 mg/kg ip) and divided into four groups from diabetes onset: those receiving a daily sc injection of saline (1 ml/kg/day), GHRP-6 (150 μg/kg/day), insulin (1-8U/day) or insulin plus GHRP-6 for 8 weeks.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, insulin plus GHRP‑6 decreased diabetes-induced cerebellar apoptosis.

    In plain wordsIn rats with diabetes, insulin plus GHRP‑6 reduced diabetes-related cerebellar cell death.

    Peptide
    GHRP-6
    Outcome
    DecreaseCerebellar apoptosis
    Study

    ratn: not reported in source

    streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    In the cerebellum, although insulin treatment increased GFAP levels (P<0.01), only the combined treatment of insulin+ GHRP-6 decreased diabetes-induced apoptosis (P<0.05).
    1 context sentence
    Summary · context
    Adult male Wistar rats were made diabetic by streptozotocin injection (65 mg/kg ip) and divided into four groups from diabetes onset: those receiving a daily sc injection of saline (1 ml/kg/day), GHRP-6 (150 μg/kg/day), insulin (1-8U/day) or insulin plus GHRP-6 for 8 weeks.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.